Business Wire

IX Acquisition Corp. Announces Pricing of $200 Million Initial Public Offering

Share

IX Acquisition Corp. (the “Company”) today announced the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit. The units will be listed on the Nasdaq Stock Market LLC (“Nasdaq”) and trade under the ticker symbol “IXAQU” beginning on October 7, 2021. Each unit consists of one share of Class A ordinary share and one-half of one redeemable warrant, with each whole warrant exercisable to purchase one share of Class A ordinary shares at a price of $11.50 per share. After the securities comprising the units begin separate trading, the shares of Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “IXAQ” and “IXAQW,” respectively. The offering is expected to close on October 12, 2021, subject to customary closing conditions.

IX Acquisition Corp., led by CEO Karen Bach, CFO Noah Aptekar and Executive Chairman Guy Willner, is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination with a company in any sector or geography, the Company intends to focus its search on companies in the Technology, Media and Telecommunications and Information and Communication Technology industries, specifically the telecommunications infrastructure, internet and technology and digital services sectors operating in Europe and emerging markets.

Cantor Fitzgerald & Co. is acting as the sole bookrunner, and Odeon Capital Group, LLC is acting as the lead manager for the offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 3,000,000 units at the initial public offering price to cover over-allotments, if any.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on October 6, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering is being made only by means of a prospectus. When available, copies of the prospectus relating to the offering may be obtained from Cantor Fitzgerald & Co., 499 Park Avenue, 5th Floor, New York, New York 10022, Attn: Capital Markets, or by email at prospectus@cantor.com.

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the initial public offering and search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement for the initial public offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

IX Acquisition Corp.
Noah Aptekar
contact@ixacq.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mundipharma and Vectura announce plans to reformulate flutiform ® (fluticasone propionate/formoterol fumarate) pressurised metered-dose inhaler (pMDI) as a commitment to reducing the product’s carbon footprint16.4.2024 11:00:00 CEST | Press release

Mundipharma and Vectura will now progress development of the reformulation of flutiform® (fluticasone propionate/formoterol fumarate) following long-term collaboration, planning and lab-scale development work. The reformulation will ultimately ensure a comparable effective product for patients and further reduce its impact on the environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416962162/en/ The productis an established pressurised metered-dose inhaler (pMDI) for the treatment of asthma, where the use of a combination product is appropriate, and has been available on the market for more than a decade.3 It currently uses the approved apaflurane hydrofluoroalkane 227 (HFA-227), a type of fluorinated greenhouse gas, as its propellant.3 European Union regulation on these types of gases aims to reduce their use, and therefore their emissions, by two-thirds by 2030.1 Work is already under way to source an alternative

Caranx Medical announces successful world first robotic assisted transcatheter heart valve implantation in an animal16.4.2024 10:30:00 CEST | Press release

Caranx Medical (‘Caranx’), a French medical device company specializing in the development of autonomous robot to democratize access to Transcatheter Aortic Valve Implantation (TAVI), a lifesaving procedure, today announced the successful world first robotic assisted heart valve (aortic valve) implantation in an animal. The assisted heart valve implantation in the animal was successfully performed by Dr. Stéphane Lopez, Caranx CMO Dr. Eric Sejor, Caranx CTO Pierre Berthet-Rayne and Caranx team. “This groundbreaking achievement is the result of hard teamwork. At Caranx Medical, we are dedicated to improving patients' lives through true innovation. This successful transcatheter robotic aortic valve implantation marks the first step toward a new generation of intelligent robots guided by AI, set to transform healthcare as we know it” says Pierre Berthet-Rayne, PhD, co-founder and CTO of Caranx. “This major medical first lies not only in the technical achievement of Caranx Medical's engine

Arthur D. Little Publishes Human After All – Latest Edition of PRISM Magazine16.4.2024 10:00:00 CEST | Press release

Arthur D. Little (ADL) has published Human After All – the latest edition of its strategy and innovation magazine PRISM. As we enter the era of AI, the first edition of 2024 highlights the importance of taking a human-centric approach to business management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416226137/en/ Arthur D. Little has published Human After All – the latest edition of its strategy and innovation magazine PRISM. (Graphic: Business Wire) The magazine features seven key articles: Optimistic global CEOs focus on people and skills in an AI future - Our lead article shares highlights from the ADL 2024 CEO Insights Study, finding that CEOs are increasingly confident of future economic success. The people-centric lab of the future – how technology and AI can play a key role in driving breakthrough innovation by enabling people to become perfect innovators. The future workforce - Recruiting and retaining vital

Magnesium Capital closes oversubscribed inaugural Fund at €135m hard cap16.4.2024 09:32:00 CEST | Press release

Magnesium Capital, the Energy Transition buyout specialist, is delighted to announce the successful close of its inaugural Fund, Magnesium Capital I, at its hard cap of €135m, exceeding the €100m Fund target. The final close occurred less than a year after the Fund’s first close with Magnesium attracting blue-clip institutional investors from the US, Europe and the UK. Magnesium focuses on profitable European companies with proven technologies or tech-enabled services that are positively impacting the decarbonisation of the production, distribution and consumption of energy. The team has been backing the buyouts of such businesses for a number of years on a direct deal basis. Since inception, Magnesium has completed seven platform investments, signed six follow-on acquisitions and exited two investments for 4.2x gross MOIC. The combined impact of these portfolio companies already directly contributes to the avoidance of over 30 million tonnes of CO2 equivalent per annum. Ian Jones, Man

MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH00216.4.2024 09:00:00 CEST | Press release

MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today reports positive topline results from its Phase 2a clinical trial with MH002 in the orphan disease indication Pouchitis. MRM Health’s MH002-PC-201 study was a multi-center, open-label clinical trial in 14 acute Pouchitis (PC) patients at multiple clinical sites in Belgium and Italy. The study was designed to evaluate safety (primary objective), initial efficacy, and mechanistic effects of MH002 over 8 weeks. More information about the trial is available at clinicaltrialsregister.eu. The trial met its primary objective with an excellent safety and tolerability at a fixed dose of 400mg per day over 8 weeks’ administration. Treatment-Emergent Adverse Events (TEAE) reported were predominantly mild and unrelated, and there was no evidence of adverse reactions related to MH002. It also demonstrated initial efficacy in clinically relevant parameters,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye